ImmusanT is a biotechnology company founded in 2010 in Cambridge, Massachusetts. The company is at the forefront of pioneering advancements for celiac disease through innovative diagnostics and therapeutic solutions. ImmusanT leverages groundbreaking findings in immunology to enhance both diagnosis and treatment methods for celiac disease. Their flagship product, Nexvax2, is a therapeutic vaccine designed to treat, prevent, and diagnose celiac disease. In addition to Nexvax2, ImmusanT is also developing a functional T-cell test to facilitate the diagnosis and ongoing monitoring of immune tolerance through peptide-based therapy.
ImmusanT operates in the biotechnology, health care, and health and wellness industries. The company recently received a Venture Round investment on 11 September 2018 from the T1D Fund. ImmusanT's dedication to revolutionizing celiac disease treatment and diagnosis makes it a compelling prospect for venture capital investment.
